01 Jul 2025 Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development Investors | Therapeutics
28 Apr 2025 Research & Development Spotlight Series, Episode 9 Investors | R&D Spotlights Series | Therapeutics
28 Apr 2025 Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting Investors | Therapeutics
28 Apr 2025 Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting Investors | Therapeutics
26 Mar 2025 Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting Investors | Therapeutics
07 Mar 2025 Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Investors | Therapeutics
29 Jan 2025 R&D Spotlight Series, Episode 8 Podcasts and Videos | R&D Spotlights Series | Therapeutics
16 Jan 2025 Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers Investors | Therapeutics